Mineralys Therapeutics
Market cap $1.28B 88.6M shares (10-Q, Oct 29, 2026) × $14.48 close Nov 17, 2026
Most recent annual filing: 2026-03-12
- Mineralys corporate updateNov 2026Mineralys corporate update, Nov 2026, routine
- Lorundrostat reimbursementNov 30, 2026Lorundrostat reimbursement, Nov 30, 2026, notable
- Lorundrostat FDA decisionDec 22, 2026Lorundrostat FDA decision, Dec 22, 2026, thesis-defining
- Lorundrostat commercial launch1H 2027Lorundrostat commercial launch, 1H 2027, routine
- Lorundrostat Tranche B financingMar 31, 2027Lorundrostat Tranche B financing, Mar 31, 2027, notable
- Lorundrostat loan covenant corporate updateSep 30, 2027Lorundrostat loan covenant corporate update, Sep 30, 2027, notable
- Lorundrostat loan corporate update2028Lorundrostat loan corporate update, 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Capital (as filed)
- Cash
- $101M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$43.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $625M cash, runway into 2028 per the update of Nov 4, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-10 UPDATE: Mineralys Therapeutics (MLYS) - The Effect Holds, the Questions Don’t Go Away 🔒 Paid
- 2026-11-05 UPDATE: Mineralys Therapeutics (MLYS) - The Patents Come Home, the Specialists Head for the Door ★ Distilled Pro
- 2026-10-20 Mineralys Therapeutics (MLYS) - Scientific Deep Dive for Lorundrostat and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Mineralys Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-20 Watch Mineralys Therapeutics (MLYS) - Scientific Deep Dive for Lorundrostat and Pipeline Products Lorundrostat will likely be approved but arrives second to AstraZeneca with no randomized advantage and faces a payer wall from generic spironolactone, making the investment case dependent on launch evidence not yet available.
- 2026-11-05 Watch UPDATE: Mineralys Therapeutics (MLYS) - The Patents Come Home, the Specialists Head for the Door Patent ownership is now clean and EV has fallen to ~$1.0B, improving the risk/reward into the PDUFA, but the specialist base is thinning and the label, ICER report, and payer coverage remain unresolved.
- 2026-11-10 Watch UPDATE: Mineralys Therapeutics (MLYS) - The Effect Holds, the Questions Don't Go Away Transform-HTN confirms durable blood-pressure effect and manageable potassium at 48 weeks, but hyponatremia remains undisclosed, the withdrawal sub-study is unreported, and the core commercial problem — second to market against AstraZeneca with a generic payer wall — is unchanged.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 19, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 8, 2026ReleaseMineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026→ BD updateTransform-HTN delivered: lorundrostat held −17.8 mmHg at week 48 and put 56% of patients below 130 mmHg, answering the durability question I flagged — but this is an open-label extension, not a randomized trial, and it doesn't move the needle on payer coverage or the AstraZeneca problem.
- Nov 4, 2026ReleaseMineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations, officer / director change · EX-99.1→ BD updateQ3 earnings confirm the launch-cost ramp is steeper than prior quarters ($37.4M G&A vs. $9.7M a year ago), the Tanabe IP transfer is finally closed, RA Capital's board representative just resigned, and a 100%-tariff risk on drug imports is disclosed for the first time—all with 7 weeks to the PDUFA.
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 3, 2026ReleaseMineralys Therapeutics to Participate in Upcoming Investor Conferences
- Oct 29, 20268-KCurrent report: material agreement, agreement terminated
- Oct 28, 2026ReleaseMineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
- Oct 28, 2026ReleaseMineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney InternationalBD extracted 1 program update from this document → MLYS pipeline
- Oct 22, 2026ReleaseMineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026BD extracted 1 program update from this document → MLYS pipeline
- Oct 19, 2026ReleaseMineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coatsvia aggregator
- Oct 19, 20268-KCurrent report: officer / director change
- Aug 11, 20268-KCurrent report: results of operations, officer / director change · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jun 3, 20268-KCurrent report: other events · EX-99.1
- Jun 3, 20268-KCurrent report: material agreement, debt / obligation
- Jun 3, 2026424B5Prospectus supplement (offering)
- May 22, 20268-KCurrent report: shareholder vote
- May 6, 20268-KCurrent report: results of operations · EX-99.1
- May 6, 202610-QQuarterly report
- Apr 8, 2026DEFA14AProxy soliciting material
- Apr 8, 2026DEF 14AProxy statement
- Mar 12, 20268-KCurrent report: results of operations · EX-99.1
- Mar 12, 202610-KAnnual report
- Mar 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 6, 2026SCHEDULE 13G/A13G amendment
- Apr 10, 2026ARSAnnual report to shareholders